Genetics

Cancer 'guardian' breaks bad with one switch

A mutation that replaces a single amino acid in a potent tumor-suppressing protein turns it from saint to sinister. A new study by a coalition of Texas institutions shows why that is more damaging than previously known.

Oncology & Cancer

Anti-cancer drug's mode of operation deciphered

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. ...

Medications

A new drug target for liver cancer

National University of Singapore researchers have discovered that the MOAP-1 protein plays a role in reducing liver cancer risk by suppressing the hyper-active cancer-promoting Nrf2 cellular signaling pathway.

Medical research

New clues to how muscle wasting occurs in people with cancer

Muscle wasting, or the loss of muscle tissue, is a common problem for people with cancer, but the precise mechanisms have long eluded doctors and scientists. Now, a new study led by Penn State researchers gives new clues ...

page 40 from 40